Log In
Print this Print this

Spritam, levetiracetam

  Manage Alerts
Collapse Summary General Information
Company Aprecia Pharmaceuticals Co.
DescriptionOral levetiracetam that produced using ZipDose Technology, which utilizes 3D printing
Molecular Target Synaptic vesicle protein (SV2A)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationSeizures
Indication DetailsAdjunct treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in epileptic children and adults
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today